
NYSE:UNH
This summary was created by AI, based on 36 opinions in the last 12 months.
UnitedHealth Group Inc (UNH) has seen a tumultuous year, with many experts highlighting the volatility stemming from changes in leadership, regulatory pressures, and rising medical costs. Positive reviews point to regaining earnings power, especially with the return of the former CEO, who is expected to manage costs effectively and steer the company towards recovery. However, there are significant concerns about the impact of government regulations and Medicare adjustments, which could pressure margins and complicate growth prospects. The consensus reflects a blend of optimism for long-term recovery juxtaposed with caution due to ongoing industry challenges and political uncertainties. In summary, while there are indicators of potential upside, the unpredictable nature of healthcare reforms in the U.S. builds a case for cautious investment.
This stock should skate through a change in administration or even another Trump term. Americans are quite happy with private healthcare solutions. 180M Americans have some sort of private health. 75% are happy with this so it would probably not be disrupted in a large way. He prefers Anthem but there is no problem with UNH.
Allan Tong’s Discover Picks UNH it trades at 28.1x PE, which is slightly higher than its peers's average of 26.5x. Return on assets is higher, though, at 7.43% vs. 6.47% as is ROE at 21.88% vs. 18.86%. UNH stock's 1.36% may seem small, but it is in line with its peers and safe at a 34% payout ratio. The street loves this name at 14 buys and two holds, but sees only 7.5% upside from here. This isn't a trade a stock, but a long-term hold that you build on dips over time. It's enjoyed a 35% move in the past 12 months and has sharply climbed since Feb. 15. It's time for this to take a breather, which is the investor's cue to enter with a stock buying opportunity. Read Buying the Dip – A Stock Buying Opportunity for our full analysis.